Psilocybin as a model of psychotic illness

This phase I human pharmacology trial (n=40), sponsored by the National Institute of Mental Health in the Czech Republic, investigates the effects of psilocybin on brain connectivity in a pharmacological model of psychosis. The trial involves healthy volunteers aged 18 to 65, excluding pregnant women and those with certain medical conditions.

Psilocybin, administered orally, will be compared to a placebo in a double-blind, crossover design. The primary endpoints include changes in regional brain activity, cognitive activation, EEG spectra, and neuropsychiatric test results. The trial aims to correlate these findings with the neurobiology of schizophrenia, providing implications for treatment. The study began in 2014 and concluded in December 2016.

Topic Healthy Subjects
Compound Psilocybin
Country Czech Republic
Visit trial

Trial Details



Trial Number

Sponsors & Collaborators

National Institute of Mental Health
This company doesn't have a full profile yet, it is linked to a clinical trial.

Data attribution

A large set of the trials in our database are sourced from ClinicalTrials.gov (CTG). We have modified these post to display the information in a more clear format or to correct spelling mistakes. Our database in actively updated and may show a different status (e.g. completed) if we have knowledge of this update (e.g. a published paper on the study) which isn't reflected yet on CTG. If a trial is not sourced from CTG, this is indicated on this page and you can follow the link to the alternative source of information.